Background: This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK- 1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF. Sponsor: Merck Sharp & Dohme Corp. Trial Registration No: NCT02861534 ( Link Trial Status: recruiting completed Enrolling Centers: Worldwide: 41 countries Core Study Team:
© Christian Mueller, 2012 - 2024 │ DisclaimerImprintWebmaster │ Last Update: July 2024
VICTORIA Dr. Dayana Flores Beate Hartmann Ph.D. Eleni Michou Dr. Matthias Diebold